SCHEMBL264092

SCHEMBL264092

C[C@]1(O)[C@@H](c2coc3c(N)ncnc23)O[C@H](CO)[C@H]1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.48
HIF1A Q16665 2/20 0.38
PI4KA P42356 2/20 0.35
PI4K2B Q8TCG2 2/20 0.35
PI4K2A Q9BTU6 2/20 0.35
PI4KB Q9UBF8 2/20 0.35
ADA P00813 1/20 0.35
ADORA3 P0DMS8 6/20 0.34
ADORA2B P29275 2/20 0.34
ADORA1 P30542 2/20 0.34
DPP4 P27487 1/20 0.34
MEN1 O00255 1/20 0.34
SLC28A1 O00337 1/20 0.34
MAP3K7 O43318 1/20 0.34
SLC28A2 O43868 1/20 0.34
GAPDH P04406 1/20 0.34
MAPK1 P28482 1/20 0.34
STAT6 P42226 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4962425 1.00 ADORA2A (0.48) ADORA2AHIF1API4KAPI4K2BPI4K2A
SCHEMBL13847085 1.00 ADORA2A (0.48) ADORA2AHIF1API4KAPI4K2BPI4K2A
SCHEMBL13843324 1.00 ADORA2A (0.48) ADORA2AHIF1API4KAPI4K2BPI4K2A
SCHEMBL264091 1.00 ADORA2A (0.48) ADORA2AHIF1API4KAPI4K2BPI4K2A
Hydrochloric Acid SCHEMBL3305326 0.99 ADORA2A (0.47) ADORA2AHIF1API4KAPI4K2BPI4K2A
SCHEMBL14406302 0.87 ADORA2A (0.39) ADORA2AADORA3ADORA2BADORA1
SCHEMBL13847172 0.87 ADORA2A (0.35) ADORA2AHIF1AADORA3
SCHEMBL264664 0.86 ADORA2A (0.42) ADORA2AHIF1API4KAPI4K2BPI4K2A
SCHEMBL14064162 0.85 ADORA2A (0.39) ADORA2AADAADORA3ADORA2BADORA1
SCHEMBL264655 0.85 ADORA3 (0.40) ADORA2AADORA3ADORA2BADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120213735-A1 THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES BIOCRYST PHARMACEUTICALS, INC. (US) 2012-08-23 US disclosed
US-20120213735-A1 THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES BIOCRYST PHARMACEUTICALS, INC. (US) 2012-08-23 US disclosed
US-8133870-B2 Therapeutic furopyrimidines and thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2012-03-13 US disclosed
US-20080300200-A1 Therapeutic Furopyrimidines and Thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300200-A1 Therapeutic Furopyrimidines and Thienopyrimidines DPYD, TYMP, TYMS ADORA2A 2082/4885HIF1A 2705/4885PI4KA 1103/4885
US-20120213735-A1 THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES DPYD, TYMP, TYMS ADORA2A 2082/4885HIF1A 2705/4885PI4KA 1103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.